- Markets
- Healthcare
- AUROLAB
AUROLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Auro Laboratories Names Shaan Jain As CFO
Dec 22 (Reuters) - Auro Laboratories Ltd AURL.BO:
NAMES SHAAN JAIN AS CFO
Source text for Eikon: ID:nBSE2bKb8v
Further company coverage: AURL.BO
(([email protected];;))
Dec 22 (Reuters) - Auro Laboratories Ltd AURL.BO:
NAMES SHAAN JAIN AS CFO
Source text for Eikon: ID:nBSE2bKb8v
Further company coverage: AURL.BO
(([email protected];;))
Auro Laboratories Says Amit Mahipat Shah Resigned As Chief Financial Officer
Sept 25 (Reuters) - Auro Laboratories Ltd AURL.BO:
AMIT MAHIPAT SHAH RESIGNED AS CHIEF FINANCIAL OFFICER OF CO WEF OCTOBER 1, 2023
Source text for Eikon: ID:nBSE4qKbv3
Further company coverage: AURL.BO
(([email protected];))
Sept 25 (Reuters) - Auro Laboratories Ltd AURL.BO:
AMIT MAHIPAT SHAH RESIGNED AS CHIEF FINANCIAL OFFICER OF CO WEF OCTOBER 1, 2023
Source text for Eikon: ID:nBSE4qKbv3
Further company coverage: AURL.BO
(([email protected];))
Auro Laboratories Says Approved Capacity Expansion In Existing Unit
Aug 23 (Reuters) - Auro Laboratories Ltd AURL.BO:
APPROVED CAPACITY EXPANSION IN EXISTING UNIT OF CO
INVESTMENT REQUIRED AT 400 MILLION RUPEES
Source text for Eikon: ID:nBSE7vXptn
Further company coverage: AURL.BO
(([email protected];;))
Aug 23 (Reuters) - Auro Laboratories Ltd AURL.BO:
APPROVED CAPACITY EXPANSION IN EXISTING UNIT OF CO
INVESTMENT REQUIRED AT 400 MILLION RUPEES
Source text for Eikon: ID:nBSE7vXptn
Further company coverage: AURL.BO
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Auro Laboratories do?
Auro Laboratories Limited is a pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients, Intermediates, and Generic Formulations, with a primary focus on Anti-Diabetic Drugs.
Who are the competitors of Auro Laboratories?
Auro Laboratories major competitors are Aarey Drugs & Pharma, Vaishali Pharma, BDH Inds, Amwill Health Care, Tyche Inds, Bal Pharma, IndoAmerican Advance. Market Cap of Auro Laboratories is ₹162 Crs. While the median market cap of its peers are ₹165 Crs.
Is Auro Laboratories financially stable compared to its competitors?
Auro Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Auro Laboratories is 3.82 and is ranked 4 out of its 8 competitors.
Does Auro Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Auro Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Auro Laboratories allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress
How strong is Auro Laboratories balance sheet?
Balance sheet of Auro Laboratories is strong. But short term working capital might become an issue for this company.
Is the profitablity of Auro Laboratories improving?
The profit is oscillating. The profit of Auro Laboratories is ₹3.48 Crs for TTM, ₹7.79 Crs for Mar 2024 and ₹2.44 Crs for Mar 2023.
Is the debt of Auro Laboratories increasing or decreasing?
Yes, The debt of Auro Laboratories is increasing. Latest debt of Auro Laboratories is ₹33.53 Crs as of Sep-24. This is greater than Mar-24 when it was ₹22.95 Crs.
Is Auro Laboratories stock expensive?
Yes, Auro Laboratories is expensive. Latest PE of Auro Laboratories is 46.43, while 3 year average PE is 19.44. Also latest EV/EBITDA of Auro Laboratories is 39.92 while 3yr average is 12.87.
Has the share price of Auro Laboratories grown faster than its competition?
Auro Laboratories has given better returns compared to its competitors. Auro Laboratories has grown at ~16.13% over the last 7yrs while peers have grown at a median rate of 4.0%
Is the promoter bullish about Auro Laboratories?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 52.18% and last quarter promoter holding is 52.15%.
Are mutual funds buying/selling Auro Laboratories?
The mutual fund holding of Auro Laboratories is stable. The current mutual fund holding in Auro Laboratories is 0.01% while previous quarter holding is 0.01%.